Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Gjörn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Format: Članak
Jezik:engleski
Izdano: Philipps-Universität Marburg 2023
Teme:
SARS-CoV-2
proteomics
COVID-19
Medizin
acute respiratory distress syndrome
Ruxolitinib
Medical sciences Medicine
Online pristup:PDF cijeli tekst
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
Publikationen im Open Access gefördert durch die UB

Slični predmeti